

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	36262	histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:17			0
2	BRS	L2	1533	1 same stabiliz\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:22			0
3	BRS	L3	182	(glucagon adj like adj peptide adj "2") or glp-2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:01			0
4	BRS	L4	1	2 same 3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:19			0
5	BRS	L5	1062	2 same (polypeptide or peptide or hormone)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:21			0
6	BRS	L6	157	5 same (composition or formulation)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:21			0
7	BRS	L7	126	5 same (composition or formulation) same phosphate	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:22			0
8	BRS	L8	17	1 near stabiliz\$3	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:42			0
9	BRS	L9	5540	glucagon	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:42			0
10	BRS	L10	1	2 same 9	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 14:42			0
11	BRS	L11	821	glucagon adj like adj peptide	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:01			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
12	BRS	L12	0	2 same 11	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:02			0
13	BRS	L13	2	6120761.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:03			0
14	BRS	L14	0	2 same 13	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:04			0
15	BRS	L15	1	2 and 13	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 15:37			0
16	BRS	L19	48231	phosphate adj buffer	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:20			0
17	BRS	L20	36262	histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:20			0
18	BRS	L21	121152	(bulking adj agent) or mannitol or sucrose	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:21			0
19	BRS	L22	2	3 same 19 same 20 same 21	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:21			0
20	BRS	L23	12	((glucagon adj like adj peptide adj "2") or glp-2) same receptor same antagonist	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:35			0
21	BRS	L24	1	kit same (((glucagon\$1 like adj peptide\$12) or glp-2) same (phosphate adj buffer) same histidine same ((bulking adj agent) or mannitol or sucrose))	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:36			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error Count
22	BRS	L25	0	((glucagon adj like adj peptide adj "2") or glp-2) same lyophiliz\$	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:36			0
23	BRS	L26	1	isaacs adj indu.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/09/13 16:36			0

FILE 'MEDLINE' ENTERED AT 16:41:18 13 SEP 2003

FILE 'CAPLUS' ENTERED AT 16:41:18 ON 13 SEP 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:41:18 ON 13 SEP 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:41:18 ON 13 SEP 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:41:18 ON 13 SEP 2003  
COPYRIGHT 2003 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 16:41:18 ON 13 SEP 2003

=> s (glucagon like peptide 2) or glp-2  
L1 1319 (GLUCAGON LIKE PEPTIDE 2) OR GLP-2

=> s phosphate buffer  
L2 77082 PHOSPHATE BUFFER

=> s histidine  
L3 162033 HISTIDINE

=> s (bulking agent) or mannitol or sucrose  
L4 376996 (BULKING AGENT) OR MANNITOL OR SUCROSE

=> s l1 (p) l2 (p) l3 (p) l4  
L5 1 L1 (P) L2 (P) L3 (P) L4

=> d l5 1 ibib abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2001:507555 CAPLUS  
DOCUMENT NUMBER: 135:97491  
TITLE: GLP-2 formulations  
INVENTOR(S): Isaacs, Indu J.  
PATENT ASSIGNEE(S): NPS Allelix Corp., Can.  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049314	A2	20010712	WO 2000-US35512	20001229
WO 2001049314	A3	20020103		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2001027180	A1	20011004	US 2000-750022	20001229
EP 1246639	A2	20021009	EP 2000-988416	20001229
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003519195	T2	20030617	JP 2001-549681	20001229
PRIORITY APPLN. INFO.:			GB 1999-30882 A	19991230
			WO 2000-US35512 W	20001229

AB The invention is directed to formulations of \*\*\*GLP\*\*\* - \*\*\*2\*\*\* peptides and analogs thereof exhibiting superior stability following storage and/or exposure to elevated temps. The \*\*\*GLP\*\*\* - \*\*\*2\*\*\* compns. comprise a \*\*\*GLP\*\*\* - \*\*\*2\*\*\* peptide or an analog thereof, a \*\*\*phosphate\*\*\* \*\*\*buffer\*\*\*, L- \*\*\*histidine\*\*\*, and \*\*\*mannitol\*\*\*.

=> d his

(FILE 'HOME' ENTERED AT 16:40:56 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:41:18 ON 13 SEP 2003

L1 1319 S (GLUCAGON LIKE PEPTIDE 2) OR GLP-2  
L2 77082 S PHOSPHATE BUFFER  
L3 162033 S HISTIDINE  
L4 376996 S (BULKING AGENT) OR MANNITOL OR SUCROSE  
L5 1 S L1 (P) L2 (P) L3 (P) L4

=> s 13 (a) stabiliz?  
L6 36 L3 (A) STABILIZ?

=> s 16 (p) 11  
L7 0 L6 (P) L1

=> s 16 (p) (protein or polypeptide or peptide)  
L8 4 L6 (P) (PROTEIN OR POLYPEPTIDE OR PEPTIDE)

=> duplicate remove 18  
DUPLICATE PREFERENCE IS 'CAPLUS, EMBASE'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n  
PROCESSING COMPLETED FOR L8  
L9 4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> d 19 1-4 ibib abs

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1993:142543 CAPLUS  
DOCUMENT NUMBER: 118:142543  
TITLE: Stabilization of microbial lipase with L-histidine  
INVENTOR(S): Naka, Yasuhiro  
PATENT ASSIGNEE(S): Amano Pharmaceutical Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04370096	A2	19921222	JP 1991-170616	19910614
JP 3152958	B2	20010403		

PRIORITY APPLN. INFO.: JP 1991-170616 19910614  
AB Histidine (I) or proteins having N-terminal histidine such as bovine serum albumin are used to abolish the inhibition of microbial lipase by bile acid salts in duodenum. A compn. contg. I and microbial lipase is useful as a pancreatin substitute for treatment of digestion-assocd. disorders. In the presence/absence of I, bile acid salts 4mM inhibited the activity of lipase of Rhizopus deleamar to degrade olive oil by 7% and 27, resp.

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 1991:77233 CAPLUS  
DOCUMENT NUMBER: 114:77233  
TITLE: Studies of synthetic helical peptides using circular dichroism and nuclear magnetic resonance  
AUTHOR(S): Bradley, Erin K.; Thomason, John F.; Cohen, Fred E.; Kosen, Phyllis Anne; Kuntz, Irwin D.  
CORPORATE SOURCE: Dep. Pharm. Chem., Univ. California, San Francisco, CA, 94143, USA  
SOURCE: Journal of Molecular Biology (1990), 215(4), 607-22  
CODEN: JMOBAK; ISSN: 0022-2836  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A set of 17-residue synthetic peptides were designed to be monomeric helices in aq. soln. CD expts. indicate the presence of helical structure in aq. soln. at low temp. and low pH. The 2-dimensional NMR results for one of the peptides show a segment of 10 residues which clearly meets all of the criteria for the existence of helical structure at both 5.degree. and 15.degree.. The 1st 4 residues of the peptide are in a largely extended conformation. Calcns. suggest that residues 5 through 14 are significantly helical at 5.degree.. When the temp. is increased, CD spectra indicate that the helical content decreases. At 15.degree. the 3JN.alpha. coupling consts. increase in the helical region, indicating an

increase in motion or conformational averaging in the helical segment. None of the peptides has pH titration behavior consistent with salt bridge stabilization of helical conformation. These data lend themselves to interpretation with the helix dipole model and specific side-chain interactions. When the N and C termini charges are removed the helical content of the peptides increases. The amt. of helicity increases as the pH is lowered, due to the ionization of His16. Much of the helical stabilization appears to be due to a specific side-chain interaction between His16 and Tyr12.

L9 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1986:502588 CAPLUS  
 DOCUMENT NUMBER: 105:102588  
 TITLE: Histidine-stabilized immunoglobulin  
 INVENTOR(S): Zolton, Raymond P.; Nasser, Jennifer A.  
 PATENT ASSIGNEE(S): Ortho Diagnostic Systems, Inc., USA  
 SOURCE: U.S., 8 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4597966	A	19860701	US 1985-689882	19850109
AU 8651892	A1	19860717	AU 1986-51892	19860107
AU 590737	B2	19891116		
CA 1285225	A1	19910625	CA 1986-499148	19860107
EP 187712	A2	19860716	EP 1986-300087	19860108
EP 187712	A3	19880803		

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE  
 JP 61218528 A2 19860929 JP 1986-1483 19860109  
 PRIORITY APPLN. INFO.: US 1985-689882 19850109

AB \*\*\*Histidine\*\*\* - \*\*\*stabilized\*\*\* therapeutic Ig preps. and a method for their manuf. are disclosed. It is particularly well suited for stabilization of human IgG preps. having a relatively low \*\*\*protein\*\*\* content. Preferred stabilized human .gamma.-globulin preps. comprise about 5 wt.% or less .gamma.-globulin, histidine at a concn. of about 0.025-0.2M, and optionally glycine at 0.05-0.5 M. The pH value of the preps. is at least 6.0 but not more than 7.0. A pH value of about 6.4 is most preferred. Cond. of the preps. is about 2-4 millisiemens at 5.degree., preferably about 2.5-3.5 millisiemens at 5.degree., and most preferably about 2.7 millisiemens at 5.degree..

L9 ANSWER 4 OF 4 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN  
 ACCESSION NUMBER: 75068732 EMBASE  
 DOCUMENT NUMBER: 1975068732  
 TITLE: Multiple aggregation states of phosphoribosyladenosine triphosphate synthetase.  
 AUTHOR: Parsons S.M.; Koshland Jr D.E.  
 CORPORATE SOURCE: Dept. Biochem., Univ. California, Berkeley, Calif. 94720, United States  
 SOURCE: Journal of Biological Chemistry, (1974) 249/13 (4119-4126).  
 CODEN: JBCHA3  
 DOCUMENT TYPE: Journal  
 FILE SEGMENT: 004 Microbiology  
 029 Clinical Biochemistry  
 LANGUAGE: English

AB The association states of phosphoribosyladenosine triphosphate synthetase from Salmonella typhimurium were studied using ultracentrifugation, gel filtration, and fluorescence spectroscopic techniques. The enzyme exists predominantly as a hexamer at 25 and 37.degree. under mild solvent conditions. At 4-7.5.degree. it aggregates to species smaller and larger than a hexamer depending on \*\*\*protein\*\*\* concentration. High ionic strength cesium chloride at 25.degree. leads to a species larger than the hexamer. Lower ionic strength, pH 10, or aging dissociate the enzyme to a dimer. The combination of low ionic strength and pH 10 can dissociate the enzyme further to a monomer. Either of the substrates or \*\*\*histidine\*\*\* \*\*\*stabilizes\*\*\* the hexamer form of the enzyme, but sodium ion is necessary for effective stabilization by histidine. Active enzyme was shown to be a hexamer under assay conditions, even when incubated under conditions leading to indefinite aggregation prior to ultracentrifugation in assay media.

(FILE 'HOME' ENTERED AT 16:40: ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:41:18 ON 13 SEP 2003

L1 1319 S (GLUCAGON LIKE PEPTIDE 2) OR GLP-2  
L2 77082 S PHOSPHATE BUFFER  
L3 162033 S HISTIDINE  
L4 376996 S (BULKING AGENT) OR MANNITOL OR SUCROSE  
L5 1 S L1 (P) L2 (P) L3 (P) L4  
L6 36 S L3 (A) STABILIZ?  
L7 0 S L6 (P) L1  
L8 4 S L6 (P) (PROTEIN OR POLYPEPTIDE OR PEPTIDE)  
L9 4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> s l1 (p) lyophiliz?  
L10 0 L1 (P) LYOPHILIZ?

=> s disease (p) l1  
L11 132 DISEASE (P) L1

=> s L11 (p) L2 (p) l3 (p) l4  
L12 0 L11 (P) L2 (P) L3 (P) L4

=> s isaacs indu/au  
L13 4 ISAACS INDU/AU

=> s l13 and l1  
L14 0 L13 AND L1

=> d his

(FILE 'HOME' ENTERED AT 16:40:56 ON 13 SEP 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 16:41:18 ON 13 SEP 2003

L1 1319 S (GLUCAGON LIKE PEPTIDE 2) OR GLP-2  
L2 77082 S PHOSPHATE BUFFER  
L3 162033 S HISTIDINE  
L4 376996 S (BULKING AGENT) OR MANNITOL OR SUCROSE  
L5 1 S L1 (P) L2 (P) L3 (P) L4  
L6 36 S L3 (A) STABILIZ?  
L7 0 S L6 (P) L1  
L8 4 S L6 (P) (PROTEIN OR POLYPEPTIDE OR PEPTIDE)  
L9 4 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)  
L10 0 S L1 (P) LYOPHILIZ?  
L11 132 S DISEASE (P) L1  
L12 0 S L11 (P) L2 (P) L3 (P) L4  
L13 4 S ISAACS INDU/AU  
L14 0 S L13 AND L1

=> log y  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
56.34	56.55

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.60	-2.60

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:47:59 ON 13 SEP 2003